×

Rhythm drug shows sustained weight reduction in patients with brain damage-related obesity

By Thomson Reuters Nov 16, 2026 | 3:09 PM

Nov 16 (Reuters) – Rhythm Pharmaceuticals said on Monday its therapy for a rare form of obesity caused by brain damage showed clinically meaningful body weight reduction in patients after two years ​of therapy.

The company was testing setmelanotide, approved by the US ‌FDA under the brand name Imcivree, in adult and pediatric patients with acquired hypothalamic obesity and a type of genetic obesity.

AstraZeneca made an offer of about $10 billion to acquire Rhythm Pharmaceuticals, Reuters reported earlier this month, citing sources, as the obesity ‌drug market ​has become one of the most coveted ⁠sectors in the pharmaceutical industry.

The ⁠long-term data on setmelanotide was presented at ObesityWeek 2026, in Washington, D.C.

In the trial, 142 participants, aged 4 years and older, were randomly assigned to receive setmelanotide or a placebo for the first year. ​After one year, all those who continued with the long-term extension received setmelanotide.

Of the 125 patients who entered the extension study, 81 ⁠completed two years of treatment, including 54 ⁠who received continuous setmelanotide and 27 who switched from ​placebo after the first year.

The trial showed that patients treated continuously with setmelanotide ​achieved an average 18.8% reduction in body mass index (BMI) after ‌two years, while those who switched from placebo to the drug after one year saw an average 16.5% reduction, according to the data.

Acquired hypothalamic obesity is a rare neuroendocrine disease that causes excess and sustained weight ⁠gain due to injuries such as tumor growth or stroke in the brain.

The hypothalamus of the brain regulates appetite and affects how the body burns ⁠calories and stores fat.

Setmelanotide ‌is designed to activate the MC4R pathway in ⁠the brain to reduce excessive hunger and help the ​body burn ‌more energy.

The company said the safety profile of ​setmelanotide was ⁠generally consistent with the previous trials in acquired hypothalamic obesity patients.

In the second year, 52 of the 125 participants had treatment-related side effects, none of which was classified as serious. One death was reported and deemed unrelated to treatment, according to the company.

(Reporting by Sneha S K in Bengaluru; Editing ​by Shinjini Ganguli)